Name: | Alfentanil |
---|---|
PubChem Compound ID: | 451047 |
Description: | A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. |
Molecular formula: | C21H32N6O3 |
Molecular weight: | 415.518 g/mol |
Synonyms: |
MOLI001620
|
Name: | Alfentanil |
---|---|
Name (isomeric): | DB00802 |
Drug Type: | small molecule |
Description: | A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. |
Synonyms: |
Alfentanyl; Alfentanilum [INN-Latin]
|
Brand: | Alfenta |
Category: | Anesthetics, Intravenous, Anesthetics, Narcotics, Analgesics, Opiate Agonists, Analgesics, Opioid |
CAS number: | 71195-58-9 |
Indication: | For the management of postoperative pain and the maintenance of general anesthesia. |
---|---|
Pharmacology: |
Alfentanil is a synthetic opioid analgesic. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeuti...
show more » |
Mechanism of Action: |
Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface ...
show more » |
Absorption: | For intravenous injection or infusion only. |
Protein binding: | 92% |
Biotransformation: | The liver is the major site of biotransformation. |
Route of elimination: | Only 1.0% of the dose is excreted as unchanged drug; urinary excretion is the major route of elimination of metabolites. |
Half Life: | 90-111 minutes |
Clearance: | 5 mL/kg/min |
Toxicity: | Symptoms of overexposure include characteristic rigidity of the skeletal muscles, cardiac and respiratory depression, and narrowing of the pupils. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|